Rec­om­men­da­tions

8.7 When choos­ing glu­cose-‍low­er­ing med­i­ca­tions for over­weight or obese pa­tients with type 2 di­a­betes, con­sid­er their ef­fect on weight. E

8.8 When­ev­er pos­si­ble, min­i­mize med­i­ca­tions for co­mor­bid con­di­tions that are as­so­ci­at­ed with weight gain. E

8.9 Weight-‍loss med­i­ca­tions are ef­fec­tive as ad­juncts to diet, phys­i­cal ac­tiv­i­ty, and be­hav­ioral coun­sel­ing for se­lect­ed pa­tients with type 2 di­a­betes and BMI ≥27 kg/m2. Po­ten­tial benefits must be weighed against the po­ten­tial risks of the med­i­ca­tions. A

8.10 If a pa­tient’s re­sponse to weight-‍loss med­i­ca­tions is <5% weight loss after 3 months or if there are significant safe­ty or tol­er­a­bil­i­ty is­sues at any time, the med­i­ca­tion should be discon­tin­ued and al­ter­na­tive med­i­ca­tions or treat­ment ap­proach­es should be con­sid­ered. A